Composition for the treatment of keratoconus

By using a combination of benzalkonium chloride, EDTA, and an emulsifier as a penetration enhancer, the complications caused by epithelial removal during corneal cross-linking were resolved. This achieved corneal cross-linking while preserving the epithelium, enhanced the biomechanical strength of the cornea, and simplified the treatment process.

CN123124978APending Publication Date: 2026-11-17AMERIGEN CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202580017037.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-02-26
Filing Date
2025-02-24
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing corneal crosslinking (CXL) treatments for keratoconus require the removal of the corneal epithelium to allow riboflavin penetration, which leads to potential complications such as pain, delayed epithelial healing, and infection. Furthermore, existing epithelial-preserving methods are not very effective and cannot effectively enhance the biomechanical strength of the cornea.

Method used

A composition containing benzalkonium chloride, ethylenediaminetetraacetic acid, and emulsifiers, especially hydroxypropyl methylcellulose, is used as a penetration enhancer to enhance the penetration of riboflavin under the corneal epithelium, thereby achieving corneal cross-linking, avoiding epithelial removal, and combined with low-power UV-A irradiation to achieve biomechanical sclerosis of the cornea.

Benefits of technology

While preserving the integrity of the corneal epithelium, it achieves similar biomechanical effects to epithelialized CXL, reduces complications, simplifies the treatment process, and improves the safety and effectiveness of the treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123124978A_ABST
    Figure CN123124978A_ABST
Patent Text Reader

Abstract

This invention relates to medical treatments, and more particularly to novel epithelial-preserving CXL regimens and the treatment of keratoconus. Specifically, this invention discloses a composition comprising benzalkonium chloride, ethylenediaminetetraacetic acid, and an emulsifier, said composition for the treatment of keratoconus and other ectasias.
Need to check novelty before this filing date? Find Prior Art

Description

Invention Field

[0001] This invention relates to a composition for medical treatment, and more particularly to a novel epithelial-preserving CXL regimen and the treatment of keratoconus. Background of the Invention

[0003] Keratoconus is a common corneal disease affecting approximately 1 in 1,500 people in the general population. It is a degenerative disease characterized by progressive thinning and bulging of the cornea, accompanied by corneal astigmatism. Without treatment, the disease progresses, leading to further vision impairment and eventually corneal blindness. This disease typically develops at a young age, with two main impacts: severely impaired vision-related quality of life and the lifelong financial burden of its treatment. If the cohesion of the cornea is disrupted, it becomes conical and progressively thins. This progressive corneal deformation primarily affects young adults and is one of the most common causes of legal blindness in young adults. Once it progresses to an advanced stage, the cornea becomes so thin that only a corneal transplant can save the patient from blindness. However, a repeat transplant is usually necessary after 15 to 20 years, and a third transplant is generally not possible. Due to a global shortage of donor corneas, most patients still face the inevitable fate of partial or complete disability. At least 5,000 people in Switzerland are affected by keratoconus, about 50,000 in Germany, and more than 5 million worldwide.

[0004] Keratoconus belongs to the family of corneal ectasia diseases, which also includes spherical keratosis, clear marginal degeneration, and post-refractive laser surgery corneal ectasia. These diseases share very similar characteristics, differing mainly in age of onset and the localized distribution of corneal thinning within the cornea. Of all ectasia diseases, keratoconus is the most common.

[0005] Corneal crosslinking (CXL) uses ultraviolet-A (UV-A) light and riboflavin to form covalent bonds between collagen and proteoglycans in the extracellular matrix, thereby enhancing the biomechanical strength of the cornea. It is currently the only technique to halt disease progression. Since the introduction of CXL, the number of corneal transplants has decreased by 50% because the disease can be stabilized before vision deteriorates to the point where a transplant is necessary. To ensure effective crosslinking, CXL treatment typically involves removing the corneal epithelium before applying riboflavin and UV light irradiation—"epi-off" CXL.

[0006] The first established CXL protocol was the Dresden protocol, which involves applying UV-A light after removing the corneal epithelium to expose the matrix, which is almost entirely composed of collagen. While it has a high long-term success rate, CXL is time-consuming and was initially limited to corneas with a stromal thickness greater than 400 μm. Therefore, other accelerated epithelial-removable CXL protocols have been proposed. However, epithelial-removable CXL can cause potential complications such as severe postoperative pain, delayed epithelial healing, long-term haze, and infection. Therefore, patients receive postoperative antibiotics, steroid drops, and lubricants until epithelial regeneration is complete, which can last up to 3 months postoperatively. Preserving the integrity of the corneal epithelium will reduce pain and help avoid other adverse events associated with CXL. Several “epithelial-preserving” (transepithelial) CXL methods have been proposed.

[0007] To date, evidence suggests that transepithelial keratomileusis (CXL) remains the most effective method for strengthening the cornea and slowing the progression of keratoconus—although transepithelial approaches are gradually being developed. While there are multiple treatment options for keratoconus and other corneal ectasias, only corneal cross-linking (CXL) can stop the progression of the disease.

[0008] The Dresden protocol requires the removal of epithelial cells because riboflavin is a large hydrophilic molecule that cannot penetrate intact epithelium composed of 5 to 6 layers of epithelial cells. Intact epithelium reduces UV transmission, consumes oxygen, and acts as a barrier to prevent the matrix from becoming saturated with riboflavin and oxygen, both of which are essential for successful cross-linking.

[0009] To address the limitations of riboflavin, several approaches have been attempted to deliver it to the stroma. One approach from 2012 to 2016 was to use permeation enhancers to increase the permeability of riboflavin. However, the described compositions were too erosive to the epithelium. With such “early” epithelial-preserving methods, epithelial necrosis often occurs in the cornea on postoperative day 1, making it essentially an epithelial ablation procedure. Gatzioufas et al. showed a high incidence of epithelial defects (46%) and punctate corneal epithelial dysplasia / corneal epithelial loosening (23%) in the transepithelial CXL method administered with a modified riboflavin solution (0.25% riboflavin and 0.01% benzalkonium chloride), which was observed immediately postoperatively (J Refract Surg. 2016; 32(6): 372-377).

[0010] Other methods include: pharmacological lysis of the tight junctions of the epithelium, application of riboflavin into the stroma via a capsule created by injection or femtosecond laser, and iontophoresis, which involves delivering molecules via electrophoresis and electroosmosis under the influence of an applied current. However, the need for additional equipment and the preparation of various forms of riboflavin for different KC stages and states increases the complexity of CXL surgery and the cost of CXL treatment. Maintaining the integrity of the corneal epithelium will eliminate wound-related complications and pain associated with deepithelialization CXL.

[0011] To address the problem of insufficient oxygen saturation, the CXL scheme, which utilizes pulsed light and increases oxygen partial pressure through oxygen goggles, has been introduced. Invention Overview

[0013] The purpose of this invention is to provide a novel epithelial-preserving CXL approach that can achieve corneal biomechanical sclerosis effects similar to those of the currently widely used accelerated epithelial-de-epithelial CXL approach.

[0014] The stated objective is achieved through the technical teachings of the independent claims. Further advantageous embodiments, aspects, and details of the invention can be found in the dependent claims, the specification, and the examples.

[0015] Surprisingly, compositions containing benzalkonium chloride, EDTA, and emulsifiers, as disclosed herein, have been found to effectively accelerate the transepithelial delivery of active agents, particularly riboflavin, into the eye while maintaining the integrity of corneal epithelial cells.

[0016] Therefore, the present invention relates to a composition comprising benzalkonium chloride, ethylenediaminetetraacetic acid and an emulsifier, said composition for treatment, particularly for a method of treating keratoconus and other corneal ectasia.

[0017] One embodiment of the invention relates to a composition used as a penetration enhancer for the transepidermal administration of an active agent, particularly riboflavin. Riboflavin, also known as vitamin B2, is a water-soluble vitamin. Unlike folic acid and vitamin B6, riboflavin is only a compound with CAS Registry No.® 83-88-5.

[0018] Description of the preferred implementation scheme

[0019] One aspect of this invention relates to the use of benzalkonium chloride and ethylenediaminetetraacetic acid (EDTA) to improve the efficiency of topical drug delivery to the eye, particularly as a penetration enhancer of riboflavin in methods of treating keratoconus and other corneal ectasias. Riboflavin or other active agents can be administered on their own or in the form of pharmacologically acceptable salts. Furthermore, riboflavin or other active agents can be administered as a separate composition after the penetration enhancer, or as part of the same composition with the penetration enhancer. Penetration enhancers (also known as absorption enhancers or adsorption promoters) are compounds that can promote the penetration of an active pharmaceutical ingredient into or through poorly permeable biological membranes. They typically permeate biological membranes and reversibly reduce their barrier properties. Topical drug delivery to the eye is generally characterized by extremely low drug bioavailability due to several natural defense mechanisms, including nasolacrimal duct drainage, blinking, and poor corneal permeability. Enhancing corneal permeability to drug molecules is one strategy to improve the efficiency of topical drug delivery to the eye.

[0020] In the embodiments described herein, the compositions described herein have been demonstrated to effectively enhance epithelial-preserving CXL regimens. The studies presented herein demonstrate that, without the application of iontophoresis, epithelial-preserving CXL regimens can achieve biomechanical effects similar to currently widely used accelerated de-epithelialized CXL regimens using only the compositions described herein. These results hold promise for unifying and simplifying current complex epithelial-preserving CXL regimens.

[0021] Benzalkonium chloride (BAC), also known as alkyl dimethyl benzyl ammonium chloride (ADBAC), traded under the name Zephiran, is a cationic surfactant with CAS registration number® 8001-54-5. BAC is a nitrogen-containing cationic surfactant belonging to the quaternary ammonium salt class, with an extremely wide range of applications. BAC is a disinfectant active substance with antibacterial and antiviral properties. Benzalkonium chloride is mainly used in the pharmaceutical industry as a multi-dose container, especially as a preservative in eye drops, nasal sprays, and inhalation solutions. In this paper, BAC is used as a penetration enhancer. The inventors believe that these effects are based on BAC acting as a surfactant to dissolve intercellular connections within the corneal epithelium, thereby enhancing drug delivery. Surprisingly, the inventors have now successfully determined the optimal concentration and composition of BAC with other ingredients to achieve optimal absorption of the active agent, while the cornea remains undamaged or at least not damaged to the extent of destruction. The compositions of this invention make it possible to deliver a sufficient amount of riboflavin while maintaining corneal integrity. Therefore, the compositions described herein can be ophthalmic preparations. Ophthalmic preparations can be administered in any form suitable for ocular administration, such as solutions, suspensions, ointments, gels, liposome dispersions, colloidal microparticle suspensions, etc. Suitable ophthalmic preparations are eye drops, preferably sterile eye drops.

[0022] In one embodiment, a composition comprising benzalkonium chloride, ethylenediaminetetraacetic acid (EDTA), and an emulsifier is provided. Benzalkonium chloride may be present in an amount of 0.005% to 0.020% by weight, preferably 0.0075% to 0.015% by weight. EDTA may be present in an amount of 0.05% to 0.20% by weight, preferably 0.075% to 0.15% by weight. The emulsifier, and particularly a cellulose derivative, may be present in an amount of 0.2% to 1.5% by weight, preferably 0.25% to 1% by weight, and even more preferably 0.5% to 0.7% by weight. EDTA is an aminopolycarboxylic acid and is widely used in the reaction of iron (Fe²⁺) with other substances. 2+ / Fe 3+ ) and calcium ions (Ca 2+ EDTA binds to metal ions, forming water-soluble complexes even at neutral pH. Therefore, in chelation therapy practice, it is used to bind metal ions, such as in the treatment of mercury and lead poisoning. It is used in a similar manner to remove excess iron from the body. This therapy is used to treat complications from repeated transfusions, as it is used to treat thalassemia. EDTA and ophthalmologically acceptable EDTA salts are suitable components. When EDTA salts are used in the mixing of compositions as described herein, the concentrations mentioned refer only to EDTA ions.

[0023] The compositions described herein can be colloidal suspensions or emulsions. Therefore, they can contain emulsifiers. Emulsifiers are substances that stabilize emulsions by reducing the interfacial tension between oil and water. Emulsifiers can be selected from or comprise of the following: ascorbate palmitate, lecithin, trisodium phosphate, tripotassium phosphate, alginate, monoglycerides and diglycerides of fatty acids, and cellulose derivatives, with cellulose derivatives being preferred, and particularly preferred being hydroxypropyl methylcellulose. Other possible cellulose derivatives are hydroxyethyl methylcellulose and carboxymethyl cellulose.

[0024] The composition described herein can be slightly hypotonic. This means that the osmotic pressure of the composition is lower than the physiologically normal value compared to the matrix osmotic pressure. In particular, its osmotic pressure can be 350 ± 10 mOsmol / kg H2O.

[0025] Without being bound by theory, it appears that the combination of benzalkonium chloride, EDTA, and emulsifiers, particularly hydroxypropyl methylcellulose, plays a crucial role. Comparison with similar compositions shows that only the combination of these three components produces the beneficial effects (enhanced riboflavin penetration, hardening effect similar to the most commonly used CXL epidermal resurfacing regimen, no corneal defects, and prevention of keratoconus progression). Furthermore, the administration regimen can be optimized to further enhance these effects. Therefore, one aspect of the invention relates to the therapeutic use of a composition comprising:

[0026] 0.005-0.02% benzalkonium chloride by weight

[0027] 0.05-0.3% by weight of ethylenediaminetetraacetic acid, and

[0028] 0.2 to 1.5% hydroxypropyl methylcellulose by weight.

[0029] Another aspect of the present invention relates to the therapeutic use of a composition comprising:

[0030] 0.005-0.02% benzalkonium chloride by weight,

[0031] 0.05-0.3% by weight of ethylenediaminetetraacetic acid, and

[0032] 0.5-1.0% hydroxypropyl methylcellulose by weight.

[0033] Emulsifiers, particularly hydroxypropyl methylcellulose (HMC), affect the viscosity of the composition. A viscosity of 0.5 to 1.2% HMC by weight is advantageous because it supports the application of the composition. However, for sterilization by filtration, a viscosity of less than 0.7% HMC by weight is beneficial. Therefore, a HMC range of 0.5 to 0.7% by weight is most suitable. Of course, viscosity is also affected by the amounts of other components and other sterilization techniques. Therefore, a wider range of 0.2 to 1.5% HMC by weight is feasible.

[0034] The composition can be brought to 100% by weight using a suitable solvent such as water or a buffer solution. Therefore, the composition of this application can be an aqueous solution. The buffer solution can be selected from or composed of the following: tris(hydroxymethyl)aminomethane, 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid, 2-[[1,3-dihydroxy-2-(hydroxymethyl)propyl-2-yl]amino]ethanesulfonic acid, 3-(N-morpholino)propanesulfonic acid, piperazine-N,N'-bis(2-ethanesulfonic acid), or a balanced salt solution rich in bicarbonate, glucose, and glutathione. Preferably, each 1 ml of water for injection contains 6.4 mg of sodium chloride (NaCl), 0.75 mg of potassium chloride (KCl), 0.48 mg of calcium chloride dihydrate (CaCl2·2H2O), 0.3 mg of magnesium chloride hexahydrate (MgCl2·6H2O), 3.9 mg of sodium acetate trihydrate (C2H3NaO2·3H2O), 1.7 mg of sodium citrate dihydrate (C6H5Na3O7·2H2O), sodium hydroxide, and / or hydrochloric acid (to adjust the pH).

[0035] Therefore, one embodiment of the present invention relates to a composition comprising:

[0036] 0.008-0.012% benzalkonium chloride by weight,

[0037] 0.05-0.15% ethylenediaminetetraacetic acid by weight,

[0038] Hydroxypropyl methylcellulose, 0.4-1% by weight.

[0039] Sodium chloride, 0.6-1.1% by weight,

[0040] Potassium chloride, by weight, 0.6-0.85%.

[0041] Calcium chloride dihydrate, 0.06-0.85% by weight.

[0042] Magnesium chloride hexahydrate, 0.3 mg% by weight.

[0043] 3.9 mg of sodium acetate trihydrate,

[0044] 1.7 mg of sodium citrate dihydrate, and

[0045] Tris(hydroxymethyl)aminomethane, 0.06-0.85% by weight.

[0046] The pH of the compositions described herein can be approximately 7.5, particularly between 7.4 and 7.6. The pH can be calibrated using tris(hydroxymethyl)aminomethane (TRIS).

[0047] The compositions described herein may additionally contain active agents, such as riboflavin. The concentration of riboflavin may be 1 to 2% by weight. The composition of the solution may be free of other components besides those disclosed above and possible active ingredients.

[0048] However, it is preferable to administer the active agent as a separate composition after the penetration enhancer. Using the composition as described herein without riboflavin (subsequently administered) allows for the use of a single solution in different corneal crosslinking protocols (epithelial ablation and epithelial-preserving CXL). This is therefore very convenient for practitioners, as they only need one solution suitable for all protocols. The concentration of riboflavin in the subsequently administered solution can be from 0.05% to 2.5% by weight, and preferably from 0.1% to 0.5% by weight.

[0049] Furthermore, the composition described herein enables the use of an epithelial-preserving regimen without requiring additional equipment besides a UV irradiation device. Therefore, this regimen can be used in any medical facility. Other epithelial-preserving regimens require separate equipment for oxygenation or electrophoresis and electroosmosis.

[0050] On the other hand, this relates to the use of the compositions described herein in treatment methods including repeated application of the compositions. The compositions can be administered over a period of 5 to 30 minutes at regular intervals of 10 seconds to 2 minutes. Preferably, the compositions can be administered over a period of 8 to 15 minutes at regular intervals of 20 seconds to 1 minute. The compositions described herein can be administered directly to the epithelium, such as the cornea, and may be followed by rinsing the epithelium after a 5-minute wait. Therefore, the compositions can be administered over a period of 5 to 30 minutes at regular intervals of 10 seconds to 2 minutes, followed by an incubation step of 3 to 10 minutes. During this incubation step, the last drop of the composition to be administered remains on the cornea. At the end of the incubation step, the surface of the cornea can be rinsed clean. It is preferred to rinse away the compositions of the invention using a balanced salt solution (BSS).

[0051] Another aspect of the invention is its use in epithelial-preserving regimens for the treatment of keratoconus and other corneal ectasias. Therefore, the application of an active agent such as riboflavin can occur after the administration of a penetration enhancer. It can be administered over a regular interval of 10 seconds to 1 minute for a total of 10 to 30 minutes, and preferably over a regular interval of 15 seconds to 30 seconds for a total of 15 to 25 minutes. The concentration of riboflavin in the compositions of the invention or the subsequently administered solutions in a buffer solution, such as sodium phosphate buffer, can be 0.05 to 1% by weight, particularly 0.075 to 0.5%, 0.1 to 0.2%, or 0.1 to 0.175% or 0.12 to 0.16% by weight. Preferably, the riboflavin solution used subsequently is carrier-free. Higher riboflavin concentrations lead to faster saturation, but they also limit the treatment depth to shallower areas because more riboflavin molecules are present per unit volume of tissue, which will be bleached by the riboflavin. Ultraviolet radiation reaching deeper layers will be reduced. Therefore, it is evident that one advantage of this composition is that it enables the use of lower concentrations of riboflavin in therapeutic applications.

[0052] UV-A irradiation is then performed. An advantage of the composition of this invention is that good results are achieved using a relatively low-power UVA device. In one embodiment, UV-A radiation can be at a rate of 9 to 30 mW / cm². 2 Applying UV-A light for 5 to 25 minutes produces 4 to 20 J / cm². 2 The total irradiation energy. UV-A light can be applied in a pulsed manner, such as being turned on for 0.5 to 2 seconds and off for 0.5 to 2 seconds. In one embodiment, UV-A radiation can be at a rate of 18 to 30 mW / cm². 2 Pulsed UV-A light applied for 10 to 20 minutes produces 5.4 to 18 J / cm². 2 The total irradiation energy. Preferably, 18 mW / cm² is used. 2 The irradiation process, involving pulsed UV-A light (1 second on / 1 second off) for 15 to 20 minutes, produces approximately 10.0 J / cm².2 (8 to 12 J / cm) 2 The total radiation energy. More preferably, the irradiation step uses 18 mW / cm². 2 Pulsed UV-A light (1 second on / 1 second off) was applied for 18.5 minutes, generating a total irradiation energy of 10.0 J / cm.

[0053] On the other hand, the present invention relates to the use of the compositions described herein as epithelial permeability enhancers. Therefore, the present invention relates to a method of treating patients with keratoconus using the compositions.

[0054] Treatment methods for keratoconus may include the following steps:

[0055] a) Applying the composition to the corneal surface, said composition comprising:

[0056] 0.005-0.02% benzalkonium chloride by weight,

[0057] 0.05-0.3% by weight of ethylenediaminetetraacetic acid, and

[0058] 0.2-1.5% by weight, and preferably 0.4-1% by weight, of hydroxypropyl methylcellulose;

[0059] b) Applying riboflavin, preferably without a drug carrier, to the corneal surface; and

[0060] c) Irradiating the corneal surface with UV-A. All aspects and features of the compositions and uses described herein also relate to the methods described herein.

[0061] The method may also include the following steps between step a) and step b):

[0062] aa) Rinse the corneal surface thoroughly with a solution adjusted to physiological pH and isotonic salt concentration (i.e., a balanced salt solution). Alternatively or additionally, the method may include applying a local anesthetic, such as buprolactin, to the eye prior to step a). The local anesthetic may be applied every 60 seconds for 3 minutes.

[0063] Brief description of the attached figures

[0064] Figure 1 The distribution and comparison of the mean elastic modulus of porcine corneas among the three study groups are shown. CXL = corneal cross-linking.

[0065] Figure 2 This paper presents a comparison of the average riboflavin fluorescence intensity levels in the cornea (300 μm depth) using different currently commercially available riboflavin formulations. 1: Deepenthesizing regimen; 2: Avedro's Paracel TM3: The composition according to the invention; 4: Ricrolin ® 5: Ribo-Cross TE SERVImed Example

[0066] Example 1

[0067] The eye drop formulation of the present invention is prepared by the following method:

[0068] A 0.1% EDTA-containing benzalkonium chloride stock solution (NRF), HPMC, and NaCl were added to a sterile rinsing solution (equilibrium salt solution, BSS Alcon) and mixed until visibly clear, indicating dissolution. The pH of the mixture was set to 7.5 using tromethamine. The formulation has the following composition:

[0069] 0.1% EDTA-containing benzalkonium chloride stock solution (NRF): 0.3000 g

[0070] HPMC: 0.0210g

[0071] NaCl: 0.0084g

[0072] Tromethamine (TRIS): 0.0021 g,

[0073] Add the balanced salt solution (BSS Alcon) to a total of 3 g.

[0074] Example 2

[0075] Freshly removed pig eyes with intact epithelium and no scars were obtained from a local slaughterhouse (Zurich, Switzerland) and used within 8 hours. The eyes were randomly assigned to different study groups.

[0076] Group 1 epithelial removal regimen;

[0077] Paracel of Avedro in Group 2 TM ;

[0078] Group 3 compositions according to the invention;

[0079] Group 4 Ricrolin®;

[0080] Group 5 SERVImed Ribo-Cross TE.

[0081] The control group is as follows:

[0082] For all eyes in the epithelial removal group, the epithelium was removed using a corneal epithelial scraper (hockey knife). After porcine cornea preparation was completed, 0.4% butyloxybrucine (Théa Pharma, Schaffhausen, Switzerland) was applied every minute for 3 minutes.

[0083] For Group 3 and the corresponding control group, the formulation of Example 1 was applied to the corneal surface every 30 seconds for a total of 10 minutes. Then, after a 5-minute wait, the corneal surface was rinsed with balanced salt solution (BSS). For Group 3, a carrier-free 0.15% low-osmolarity riboflavin solution (Ribo-Ker, EMAGine, Zug, Switzerland) was applied to the corneal surface every 20 seconds for 20 minutes. For Group 1, the same riboflavin dropping protocol was used directly without applying the composition according to Example 1.

[0084] Avedro (now Glaukos)'s ParaCel™ refers to a two-step transepithelial riboflavin regimen that uses two different solutions specifically formulated for direct application to intact epithelium, used according to the manufacturer's instructions. For group 1, solution 1 (0.25% riboflavin) is applied to the corneal surface every 60 seconds for a total of 4 minutes. Immediately thereafter, treatment continues with solution 2 (0.22% riboflavin), applied to the corneal surface every 20 seconds for 6 minutes.

[0085] Group 4 treatment involved the application of Ricrolin+ using iontophoresis. Therefore, an iontophoresis aspiration ring was placed and positioned centrally on the corneal surface. Riboflavin was administered and transferred via the I-ON CXL electrodelivery system: 1 mA.

[0086] After 5 or 10 minutes of aspiration, aspirate any excess solution with a syringe and thoroughly rinse the eye surface with sterile saline Na-Cl solution to remove all residual riboflavin from the corneal surface.

[0087] The fifth group of corneas was treated with RiboCrossTE for 15 minutes, with each treatment lasting 5 to 10 seconds. Excess solution was then removed with a dry triangular sponge.

[0088] Each group included a negative control group (cornea, riboflavin-free solution) and a positive control group (riboflavin administered for 20 minutes during the deepithelialization regimen), and measurements were taken simultaneously.

[0089] The amount of riboflavin detectable at a depth of 310 µm in the cornea immediately after treatment was used as the primary result to be measured. Therefore, the treated cornea was rinsed with PBS, the epithelium was removed, and it was placed in a 5 mm chamber with the anterior surface facing upwards using a biopsy punch. The detection window used was 500–550 nm. The data obtained using the composition of the present invention are excellent compared to other known compositions. Results are as follows... Figure 2 As shown in the diagram. For group 3, different parameters were changed: using 0.12% riboflavin did not significantly alter the results. Without incubation after pretreatment with the composition of the present invention, the amount of riboflavin detected was lower, but the difference was not significant. Furthermore, incubation for 10 minutes instead of 5 minutes showed only a slight increase in the detected riboflavin, which was not a significant change. Incubation for 20 minutes did not further affect the results.

[0090] Example 3

[0091] The inventors can demonstrate that, without the application of iontophoresis, the epithelial-preserving CXL regimen can achieve similar biomechanical effects to the currently widely used accelerated epithelial de-epithelialization CXL regimen simply by using an epithelial permeability enhancer.

[0092] Fifty freshly excised pig eyes with intact epithelium and no scarring were obtained from a local slaughterhouse (Zurich, Switzerland) and used within 8 hours. These eyes were randomly assigned to three study groups (n=50 per group). One group was used for the epithelial preservation protocol, another for the epithelial removal protocol, and the third served as a control group. For all eyes, anterior segment optical coherence tomography (AS-OCT) combined with Placido-based corneal topography (MS-39, CSO Italia, Firenze, Italy) was used to record corneal epithelial and total thickness, as well as corneal curvature information.

[0093] The composition according to the invention was prepared by mixing 0.01% BAC, 0.1% EDTA, and 0.7% hydroxypropyl methylcellulose (HPMC) by weight. The solution was brought to 100% by weight with BSS having an osmolarity of 350 mM, and the pH was set to 7.5 using TRIS buffer.

[0094] For pig eyes in the epithelium-preserving group and the control group, phototherapy-assisted keratotomy (PTK) was performed using an Amaris 750S excimer laser (Schwindeye-tech solutions GmbH, Kleinostheim, Germany). The epithelial ablation depth of PTK was calculated based on the measured epithelial thickness, ensuring a remaining central epithelial thickness of 55 µm. The PTK ablation range for all ablated eyes was set to a maximum of 10 mm. For all eyes in the epithelium-removing group, the epithelium was removed using a corneal epithelial curette.

[0095] After all porcine corneas were prepared, 0.4% butoxybrucine (Théa Pharma, Schaffhausen, Switzerland) was applied every minute for 3 minutes. For the epithelial preservation group and the control group, the composition according to the invention was applied to the corneal surface every 45 seconds for a total of 10 minutes. Then, after waiting for 5 minutes, the corneal surface was rinsed with balanced salt solution (BSS), and 0.1% hypotonic riboflavin solution (Ribo-Ker, EMAGine, Zug, Switzerland) without other carriers or drug solvents was applied to the corneal surface every 20 seconds for 20 minutes. For the epithelial removal group, the same riboflavin dropping protocol was applied directly without applying the composition according to the invention.

[0096] Then, all corneas (except those in the control group) were irradiated with 365 nm UV-A light using the same crosslinking device (C-eye; EMAGine AG, Zug, Switzerland). For the epithelial preservation group, 18 mW / cm² light was applied. 2 Pulsed UV-A light (1 second on / 1 second off), lasting 15 minutes, produces 8.1 J / cm². 2 The total irradiation energy; while for the epithelialized group, 9 mW / cm² was applied. 2 Continuous UV-A light, lasting 10 minutes, produces 5.4 J / cm². 2 Total irradiation energy.

[0097] Prior to biomechanical measurements, corneal-scleral strips were taken from all corneas. Two 5 mm wide corneal-scleral strips were prepared along the center of the horizontal axis in each cornea. To standardize hydration of all corneas, all corneal-scleral strips were immersed in phosphate-buffered saline (PBS) solution at 400 mM mol / L for 15 minutes.

[0098] Stress-strain elongation measurements were performed. In short, the distal 4 mm of each corneal-scleral strip was dedicated to fixation, leaving approximately 11 mm of central corneal strip length for elongation measurement. Tensile strength was measured using a stress-strain elongator (Z0.5; Zwick GmbH & Co., Ulm, Germany), with a calibration distance accuracy of 2 mm and a measurement uncertainty of ≤0.21% between 0.25 N and 50 N for the tensile sensor. This elongator features a linear retainer extension arm that moves at a controllable speed, and the instrument is capable of measuring the real-time force (in Newtons) exerted by the arm on the held specimen. The force-to-stress conversion was calculated based on the sample width and thickness. During the adaptation period, the arm speed was 2 mm / min; during the testing phase, the position was controlled at the point of load application.

[0099] Biomechanical characterization included elasticity tests with a standard force of up to 4 N. For analysis, stress-strain curves were considered because their slope corresponds to the tangential modulus of elasticity, and measurements were taken between 5% and 10% strain. Data analysis was performed using Xpert II testing software (Zwick GmbH & Co., Ulm, Germany).

[0100] Statistical analysis was performed using R software (version 4.2.0, R Foundation for Statistical Computing, Vienna, Austria). The Shapiro-Wilks test was used to verify the normality of the data distribution. Descriptive statistics are expressed as mean ± standard deviation. For continuous variables, one-way ANOVA or the Kruskal-Wallis H test was performed to analyze equivalence between groups. A p-value < 0.05 was considered statistically significant.

[0101] In the epithelial-preserving group, the epithelial-removing group, and the control group, the mean elastic modulus as a function of strain between 5% and 10% was 5.21 ± 1.58 N / mm, 4.95 ± 1.50 N / mm, and 4.01 ± 1.41 N / mm, respectively. The distribution and comparison among the groups are as follows: Figure 1 As shown in the figure. There was no significant difference in elastic modulus between the epithelial-preserving group and the epithelial-de-epithelial group (P=0.45), but significant differences were found between the two crosslinking groups and the control group (P<0.001 and P=0.001, respectively). Therefore, it can be concluded that the compositions of the present invention enable the epithelial-preserving CXL regimen to provide a sclerosis effect similar to the most commonly used epithelial-de-epithelial CXL regimen, and have the potential to replace the latter in clinical practice.

[0102] The inventors can further demonstrate that the clinical results are excellent. The epithelium of treated patients remained intact both immediately after administration and one day later. Secondary results indicate that patients experienced improved vision after treatment with the composition comprising the present invention (as described above).

Claims

1. A composition for treatment, comprising: 0.005-0.02% benzalkonium chloride by weight, 0.05-0.3% by weight of ethylenediaminetetraacetic acid, and 0.2-1.5% hydroxypropyl methylcellulose by weight.

2. The composition according to claim 1, and its method of treating keratoconus and other corneal ectasia.

3. The composition according to claim 1 or 2, used as a permeation enhancer for transepithelial administration of riboflavin.

4. The composition according to any one of claims 1 to 3, wherein the composition is hypotonic.

5. The composition according to claim 4, wherein the composition comprises a balanced salt solution as a solvent.

6. The composition according to any one of claims 1 to 5, wherein the composition comprises: 0.008-0.012% benzalkonium chloride by weight, 0.05-0.15% ethylenediaminetetraacetic acid by weight, Hydroxypropyl methylcellulose, 0.4-1% by weight. Sodium chloride, 0.6-1.1% by weight, Potassium chloride, 0.5-0.75% by weight. 0.06-0.85% calcium chloride dihydrate by weight, and Tris(hydroxymethyl)aminomethane, 0.06-0.85% by weight.

7. The composition according to any one of claims 1 to 6, wherein the composition does not contain riboflavin.

8. The composition according to any one of claims 1 to 7, for use in a treatment method comprising repeated administration of the composition.

9. The composition according to any one of claims 1 to 8, wherein the composition is administered at regular intervals of 10 seconds to 2 minutes.

10. The composition of claim 9, wherein the composition is administered for a total of 5 to 30 minutes.

11. The composition of claim 10, wherein the composition is administered for a total of 5 to 30 minutes at regular intervals of 10 seconds to 2 minutes, followed by a 5-minute incubation interval, and then the corneal surface is rinsed clean.

12. The composition according to any one of claims 1 to 11, wherein riboflavin is subsequently administered.

13. The composition of claim 12, wherein the riboflavin is administered for 5 to 30 minutes at regular intervals of 10 seconds to 1 minute in a buffer solution of 0.1 to 0.5% by weight.

14. The composition according to claim 12 or 13, wherein the riboflavin is administered without a carrier.